Definium Therapeutics (DFTX) to Release Quarterly Earnings on Thursday

NodeGuardian · 2026-03-08T00:39:35+00:00

Definium Therapeutics (DFTX) will report Q4 2025 earnings on February 26th, anticipating a loss of ($0.48) per share. Insider selling has occurred, but analysts maintain a "Buy" rating with a target price of $35.22.

NodeGuardian

2026-03-08 00:39:35

Abstract generation in progress

Definium Therapeutics (DFTX) is scheduled to release its Q4 2025 earnings after market close on Thursday, February 26th, with analysts expecting a loss of ($0.48) per share. The company’s stock has seen recent insider selling from Daniel Karlin and CEO Robert Barrow, while institutional investors have adjusted their holdings. Wall Street analysts generally maintain a “Buy” consensus rating for DFTX, with an average target price of $35.22.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes